Valneva’s Chikungunya Vaccine Shows Promise in Children: Phase 2 Results and Phase 3 Dose Decision Announced!
Valneva’s Chikungunya Vaccine Shows Promise in Children: Phase 2 Results and Phase 3 Dose Decision Announced! Saint-Herblain (France), January 22, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of